Skip to main content

SYSTEMATIC REVIEW article

Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1385318

A Network Meta-Analysis: Evaluating the Efficacy and Safety of Concurrent Proton Pump Inhibitors and Clopidogrel Therapy in post-PCI Patients

Provisionally accepted
Ming-Ying Ai Ming-Ying Ai Yan-Zuo Chen Yan-Zuo Chen Chien-Liang Kuo Chien-Liang Kuo Wei-Lun Chang Wei-Lun Chang *
  • Far Eastern Memorial Hospital (FEMH), Xinbei, Taiwan

The final, formatted version of the article will be published soon.

    The objective of this research was to evaluate the risk of major adverse cardiovascular events (MACEs) associated with the use of various proton pump inhibitors (PPIs) in combination with clopidogrel in patients who have undergone percutaneous coronary intervention (PCI).To accomplish this, we analyzed data from randomized controlled trials and retrospective cohort studies sourced from key electronic databases. These studies specifically examined the effects of different PPIs, such as lansoprazole, esomeprazole, omeprazole, rabeprazole, and pantoprazole, when used in conjunction with clopidogrel on MACEs. The primary focus was on the differential impact of these PPIs, while the secondary focus compared gastrointestinal (GI) bleeding events in groups receiving different PPIs with clopidogrel versus a placebo group. This study's protocol was officially registered with INPLASY (INPLAS202420009). We conducted a network meta-analysis involving 16 studies with a total of 145,999 patients. Our findings indicated that Rabeprazole, when combined with clopidogrel, had the lowest increase in MACE risk (effect size: 1.

    Keywords: Major adverse cardiovascular events (MACEs), Gastrointestinal (GI) bleeding, clopidogrel, Proton pump inhibitors (PPIs), post-percutaneous coronary intervention (PCI)

    Received: 12 Feb 2024; Accepted: 01 Jul 2024.

    Copyright: © 2024 Ai, Chen, Kuo and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wei-Lun Chang, Far Eastern Memorial Hospital (FEMH), Xinbei, Taiwan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.